title: Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.
abstract: OBJECTIVE
  Gemcitabine is an effective agent in pancreatic adenocarcinoma. Fixed-dose-rate gemcitabine has an interesting biological and clinical rationale, with successful results in previous studies. We conducted a trial to confirm efficacy and toxicity of fixed-dose-rate gemcitabine in patients with pancreatic or biliary tree adenocarcinoma.
  
  
  METHODS
  Eligible patients with locally advanced or metastatic pancreatic or biliary tree adenocarcinoma received fixed-dose-rate gemcitabine at a dose of 1500 mg/m(2) at a rate of 10 mg/m(2)/min weekly for 3 weeks every 28 days. Efficacy measures were overall survival, response rate and progression-free survival.
  
  
  RESULTS
  Sixty-two patients were enrolled, and 59 were assessable for response. Seven patients (11.3%) had a partial response, 26 stable disease (41.9%) and 26 progressive disease (41.9%). Median time to progression was 21 weeks and median overall survival, 37.71 weeks. Main toxicities were grade 3-4 neutropenia (45.2%) and grade 2-3 asthenia (54.8%). No toxic deaths were documented.
  
  
  CONCLUSIONS
  Fixed-dose-rate gemcitabine has a relevant antitumor activity but with significant toxicity. It represents an interesting schedule and could be combined with other biological or chemotherapeutic agents.
authors.affiliation: Medical Oncology Department, Hospital de Cruces, Pza Cruces s/n, Barakaldo, Spain. juanmanuel.manemartinez@osakidetza.net
authors.forename: Joan M
authors.initials: JM
authors.lastname: Mané
authors.forename: Aintzane
authors.initials: A
authors.lastname: Sancho
authors.forename: Alberto
authors.initials: A
authors.lastname: Muñoz
authors.forename: Itziar
authors.initials: I
authors.lastname: Rubio
authors.forename: Ricardo
authors.initials: R
authors.lastname: Fernández
authors.forename: Sergio
authors.initials: S
authors.lastname: Carrera
authors.forename: Natalia
authors.initials: N
authors.lastname: Fuente
authors.forename: David
authors.initials: D
authors.lastname: Ballesteros
authors.forename: Raquel
authors.initials: R
authors.lastname: Casas
authors.forename: Inés
authors.initials: I
authors.lastname: Marrodán
authors.forename: Xabier
authors.initials: X
authors.lastname: Mielgo
authors.forename: Guillermo
authors.initials: G
authors.lastname: López-Vivanco
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001661:Biliary Tract Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine